Headlines
- ImmuneWorks Sponsors Pulmonary Fibrosis Foundation’s Inaugural IPF Summit 2011: From Bench to Bedside Scientific Conference
- ImmuneWorks Supports Pulmonary Fibrosis Week by Increasing National Recruitment Efforts to Enroll Idiopathic Pulmonary Fibrosis (IPF) Patients in Clinical Trial
- Biotechnology Firm ImmuneWorks Begins National Clinical Trial for New Idiopathic Pulmonary Fibrosis (IPF) Investigational Treatments
The ImmuneWorks Focus: Autoimmune Lung Diseases
ImmuneWorks is a biotechnology company that focuses exclusively on autoimmune diseases of the lung. All of our efforts are concentrated on the research and development of new potential therapies to treat idiopathic pulmonary fibrosis (IPF) and prevent lung transplant rejections.
Idiopathic Pulmonary Fibrosis Clinical Trial
ImmuneWorks has completed enrollment of patients in our Phase I clinical trial for idiopathic pulmonary fibrosis (IPF), and we are in the process of completing the trial.